Symptomatic Inoperable Plexiform Neurofibromas Therapeutics
1. Koselugo patent expiration
Treatment: Treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
KOSELUGO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(11 months from now) | |
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(11 months from now) | |
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(2 months from now) | |
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364684 | ASTRAZENECA | NA |
Mar, 2029
(3 years from now) | |
| US11813246 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| US12318367 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| US12220403 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| ODE*(ODE*) | Apr 10, 2027 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
| New Product(NP) | Sep 10, 2028 |
| New Patient Population(NPP) | Sep 10, 2028 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
Market Authorisation Date: 10 September, 2025
Dosage: GRANULE; CAPSULE
More Information on Dosage
KOSELUGO family patents
